This excerpt taken from the EYE 8-K filed Nov 2, 2005.
Laser Vision Correction:
Total laser vision correction (LVC) sales, which included the benefits of the VISX acquisition and AMO microkeratome sales, rose to $50.4 million, compared to AMO microkeratome and
other related sales of $2.8 million in the same period last year.
LVC licensing and related sales totaled $31.2 million, up approximately 15 percent compared to VISXs reported licensing and related sales in the same period last year. The
improvement reflects higher CustomVue procedures,
due in part to the fact that AMO has the widest treatment range of wavefront-guided approvals in the U.S.
LVC system sales were $11.1 million in the quarter, up approximately 71 percent compared to VISXs reported system sales in the same period last year. The rise reflects the
increase in new unit placements in targeted international markets, as well as the September rollout of Iris Registration in the U.S. LVC service and parts sales were $5.4 million in the quarter, up approximately 7 percent compared to VISXs
reported service and parts sales in the same period last year.
Bet you've never seen portfolio analytics like these.